Frostberg, Erik by unknown
Syddansk Universitet
Infliximab's influence on anastomotic strength and degree of inflammation in intestinal
surgery in a rabbit model
Frostberg, Erik; Ström, Petter; Gerke, Oke; Qvist, Niels
Published in:
B M C Surgery
DOI:
10.1186/1471-2482-14-23
Publication date:
2014
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Frostberg, E., Ström, P., Gerke, O., & Qvist, N. (2014). Infliximab's influence on anastomotic strength and
degree of inflammation in intestinal surgery in a rabbit model. B M C Surgery, 14(1), 23. DOI: 10.1186/1471-
2482-14-23
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. sep.. 2018
Frostberg et al. BMC Surgery 2014, 14:23
http://www.biomedcentral.com/1471-2482/14/23RESEARCH ARTICLE Open AccessInfliximab’s influence on anastomotic strength
and degree of inflammation in intestinal surgery
in a rabbit model
Erik Frostberg1*, Petter Ström1, Oke Gerke2 and Niels Qvist1Abstract
Background: Infliximab, a TNF-α inhibitor, is a potent anti-inflammatory drug in the treatment of inflammatory
bowel diseases. Recent studies have investigated the effect of infliximab treatment on postoperative complications
such as anastomotic leakage, however, with conflicting results and conclusions. The purpose of this study was to
investigate whether a single dose infliximab has an adverse effect on the anastomotic healing process, observed as
reduced anastomotic breaking strength and histopathologically verified lower grade of inflammatory response, in
the small intestine of a rabbit.
Methods: Thirty New Zealand rabbits (median weight 2.5 kg) were allocated to treatment with an intravenous
bolus of either 10 mg/kg infliximab (n = 15) or placebo (n = 15). One week later all rabbits underwent two separate
end-to-end anastomoses in the jejunum under general anesthesia. At postoperative day three, the anastomotic
breaking strength was determined and histopathological changes were examined.
Results: The mean value of anastomotic breaking strength in the placebo group was 1.89 ± 0.36 N and the
corresponding value was 1.81 ± 0.33 N in the infliximab treated rabbits. There was no statistically significant
difference between the groups (p = 0.51). The infliximab-treated rabbits had a significant lower degree of
inflammatory infiltration response compared to the placebo group (p = 0.047).
Conclusions: Our conclusion, limited by the small sample sizes in both groups, is that a single dose of infliximab,
given one week prior to surgery, does not have an impact on the anastomotic breaking strength on the third
postoperative day in the small intestine of rabbits.
Keywords: Infliximab, Intestinal anastomosis, Rabbits, Tensile strength, Wound healingBackground
Numerous systemic and local factors play a central role
in the healing of intestinal anastomoses [1]. Important
factors in extracellular matrix are collagen fibers, fibro-
blasts and immune cells that regulate wound strength in
the early postoperative healing process [2,3]. In the nor-
mal inflammatory response, monocytes migrate into the
wound where they are transformed into macrophages.
The tumour necrosis factor-α (TNF-α) molecule is pri-
marily released by the macrophages and since TNF-α
stimulate the collagenase production, inhibit collagen* Correspondence: erik.frostberg@rsyd.dk
1Surgical Department A, Odense University Hospital, Sdr. Boulevard 29, 5000
Odense, C, Denmark
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reproduction in any medium, provided the orsynthesis and increase fibroblast proliferation and pro-
duction of interleukin-6 and prostaglandin E2, it is
considered to be one of many important chemical in-
flammatory mediators essential for tissue remodelling
and wound healing [4,5]. Infliximab (IFX) is a chimeric
anti-tumour necrosis factor monoclonal antibody that
binds to TNF-α molecules with high affinity. Due to this
mechanism, it effectively inhibits the TNF-α molecule’s
multiple biological properties related to inflammation
and proliferation [6].
IFX has shown to be effective in the treatment of pa-
tients with inflammatory bowel disease, such as Crohn’s
disease [7-9] and ulcerative colitis [10,11]. However, due
to treatment failure many of these patients still require
surgery [12-14]. Some studies have shown an increasedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Frostberg et al. BMC Surgery 2014, 14:23 Page 2 of 8
http://www.biomedcentral.com/1471-2482/14/23risk of anastomotic leakage and other postoperative
complications in patients preoperatively treated with IFX
[15-17], and other studies have found no increased risk
[18-22]. The discrepancy between these results could be
due to different study designs and patient material. Two
recent experimental animal studies, with intestinal anas-
tomoses in rats, suggest that TNF-α inhibitor do not
have a significant impact on the anastomotic healing
process, measured by anastomotic breaking strength and
low TNF-α levels in blood and tissue samples [23,24].
However, it is suggested that the biological properties of
IFX may have other possible effects on anastomotic
wound healing [24] and therefore further research re-
garding possible effect of IFX on the intestinal healing
process is warranted.
The purpose of this study was to investigate whether a
single dose IFX has an adverse effect on the anastomotic
healing process, observed as reduced tensile strength
and histopathologically verified lower grade of inflamma-
tory response, in the small intestine of a rabbit.
Methods
Animals
Thirty female New Zealand rabbits, three months old
and with a median weight of 2.5 kg (range 2.0 to 3.1 kg)
were included. Female rabbits were used throughout the
study to avoid gender as a potential confounding factor,
although gender is not a factor in the healing of small
intestinal anastomoses [25]. All rabbits were housed in
wire cages with a shelter and plateau, including wood
shavings and hay. They were kept at room temperature
(18–20°C) with 40-60% humidity and a 12-hour light/
dark cycle. All rabbits had access to standard laboratory
diet and water as needed, and they were acclimatized for
seven days before surgery.
Study design
The animals were randomized to treatment with IFX
(n = 15) or placebo (n = 15). The treatment group received
a single bolus (10 mg/kg) of infliximab (REMICADE,
Centocor, Leiden, Holland) intravenously, and the placebo
group received the same volume of isotonic saline. The
rabbits underwent surgery one week after medication and
were sacrificed at the third postoperative day (POD3)
based on the results (unpublished) from a pilot study,
where we found a rupture in the anastomotic line in 66%
of the anastomosis on POD3 and in only 14% of the
anastomosis on POD7. Our interpretation was, that the
anastomosis was weaker in the POD3 group, which is sup-
ported by the fact that at this time the inflammatory reac-
tion in wound healing is high and gradually replaced by
the proliferating phase. In addition to this, it is well known
that anastomotic leakage most often develop from POD3
to POD5. The exact time course of strength developmentin the rabbit small intestine is to our knowledge not avail-
able in the literature.
Surgical procedures
All rabbits were sedated with a 0.3 ml/kg mixture of
fentanyl citrate 0.315 mg/ml and fluanisone 10 mg/ml
(HYPNORM, Vetpharma, Leeds, United Kingdom) ad-
ministered subcutaneously together with 2 mg/kg of mi-
dazolam (DORMICUM, 5 mg/ml; Roche, Basel, Schweiz).
In addition 10 mg/kg of propofol (PROPOVET, 10 mg/ml,
Abbott Laboratories Ltd, Berkshire, Great Britain) was
given intravenously. After sedation, all rabbits were intu-
bated with a size 3.5 endotracheal tube (Rüsch, Kernen,
Germany). The animals were anesthetized with 4 vol.%
sevoflurane (SEVOFLURANE, Abbott Scandinavia AB,
Solna, Sweden) via a MCM 801-ventilator (Dameca,
Rødovre, Denmark). For perioperative analgesia, fentanyl
(HALDID, 50 μg/ml, Janssen-Cilag, Beerse, Belgium) was
administered intravenously at a rate of 5 ml/hour using an
infusion pump (Terumo STC-526, New Jersey, USA). The
rabbits were monitored by a pulse oximeter (NONIN
8500 V, Nonin Medical, Minnesota, USA).
Under aseptic conditions, a 4 cm midline laparotomy
was made and the extremitas appendices vermiformis caeci
was identified. Two separate end-to-end anastomoses
were made, approximately 25 and 50 cm proximal to the
appendix. All anastomoses were made with interrupted
inverted single-layer 5–0 non-absorbable sutures (PRO-
LENE, Ethicon, Johnson & Johnson Nordic, Birkerød,
Denmark). The musculofascial layer was closed with inter-
rupted 3–0 absorbable sutures (VICRYL, Ethicon, Johnson
& Johnson Nordic, Birkerød, Denmark) and the skin
with a continuous 4–0 non-absorbable suture intracutane-
ously (ETHILON, Ethicon, Johnson & Johnson Nordic,
Birkerød, Denmark). Prior to skin incision 0.2 ml/kg of a
mixture of sulfadoxin 200 mg/ml and trimethoprim
40 mg/ml (DUOPRIM VET, Intervet International B.V,
Boxmeer, Holland) was given intravenously and 5 ml of
isotonic saline were administrated subcutaneously after
the surgery.
At POD3, the rabbits were euthanized with an overdose
of 2 ml intravenous pentobarbital (PENTOBARBITAL,
200 mg/ml; KU Life, Copenhagen, Denmark). A relaparot-
omy was performed and the two anastomoses were identi-
fied and carefully freed from adhesions. The anastomoses
were resected with a 2 cm margin on each side, and
cleaned for fecal contents with saline. The sutures were
left in place. The proximal anastomosis was used to test
anastomotic breaking strength and the distal anastomosis
to histopathological analysis.
The choice of performing the anastomoses in the small
intestine was justified by the fact that the majority of
intestinal resections in inflammatory bowel disease in-
volve small intestines and/or proximal colon. Another
Table 1 Descriptive statistics on the rabbits included in
the study
Parameter Placebo (N = 13) Treatment (N = 14) p-value
Number of sutures
Mean 14.5 14.5 0.80*
Anastomotic breaking strength (N)
Mean 1.89 1.81 0.51*
Std. dev 0.36 0.33
Minimum 1.34 1.32
Maximum 2.46 2.31
*Mann–Whitney U test (Wilcoxon rank-sum test).
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rabbit colon is significant different from humans and
anastomosis on/to the colon would necessitate extensive
mobilization of the colon with increased risk of post-
operative morbidity, which could be a confounding
factor.
Anastomotic breaking strength
The proximal anastomosis was mounted, with 20 mm
between the clamps and with the anastomosis in the mid-
dle, in a testing machine (LF Plus; Lloyds Instruments,
Fareham, UK) equipped with an XLC 10 N load cell
(Lloyds Instruments, Fareham, UK). The intestine was
stretched at a constant deformation rate of 10 mm/min.
The anastomotic breaking strength, defined as the mini-
mal strength necessary to rupture the anastomosis, was
derived from the load-strain curve calculated by the soft-
ware (Nexygen, Lloyds Instruments, Fareham, UK). The
site of rupture was noted as either; located in the anasto-
mosis or outside the anastomotic line.
Although the specimen was mounted in the machine
with precise accuracy, there always was the uncertainty
about the tension test machine to apply an equally dis-
tractive force to the entire circumference in each speci-
men. To minimize this possible error, we programmed
the test to start recording after the specimen had been
subjected to a tension of 0.1 N. By doing this, we had
the opportunity to detect signs on distraction, and we
could interrupt the test, remount the specimen and re-
start if necessary.
Histopathological analysis
A sample of the distal anastomosis with the sutures in situ
was fixed in 4% formaldehyde. The sample was dehy-
drated and embedded in paraffin blocks and sliced 3 μm
thin perpendicular to the anastomotic line. Staining was
made with hematoxylin and eosin. A conventional bi-
nocular Leica DMR (Leica Microsystems A/S, Herlev,
Denmark) light microscope with objective 40/0.75 was
used. The area within two millimetres related to the anas-
tomotic line was examined and the grade of inflammatory
infiltration response in the anastomotic line was scored
using a four-graded scale, with a 0–3 point value; absent
(0 points), slight (1 point), mild (2 points) and intense
(3 points). The examiner of the histological specimens
was blinded with regard to treatment group to avoid bias.
Statistical analysis
Due to the lack of a priori information for sample size
calculations, we conducted an interim analysis in order
to adjust for the final sample size. Results from that
interim analysis, based on 6 rabbits treated with IFX,
suggested the anastomotic breaking strength on small
intestinal anastomosis to be 1.61 N with a standarddeviation of 0.3. Assuming a true, clinical significant dif-
ference of 20% between the groups with respect to anas-
tomotic breaking strength, 14 rabbits in each group were
sufficient to show a statistical significant difference bet-
ween the groups with a power of 80% at a significance
level of 5% (two-sided). Drop-outs were not replaced
due to time constraints.
The data was analyzed according to type, i.e., categorical
variables were presented as frequencies and corresponding
percentages and continuous variables by mean ± standard
deviation (SD). The assumption of a normal distribution
of data was assessed visually by means of a quantile-
quantile plot for the respective variable. Student’s t-test
with unequal variances was applied to compare the
weight loss between the groups. Mann–Whitney U test
(Wilcoxon rank-sum test) was performed to compare the
weight, anastomotic breaking strength and number of su-
tures between the groups. Fisher’s exact test (two-sided)
was used to test the site of rupture and to compare the
histological parameters between the groups. P-values <0.05
were considered statistically significant without adjustment
for multiple testing. The sample size calculation and statis-
tical analysis was performed using Stata/IC 11.0 (StataCorp
LP, College Station, Texas, USA).Ethical considerations
The project was performed at the central animal facility
of the University of Southern Denmark, and a approval
(No. 2005/561 − 1066) to perform the project was
granted by the Danish Animal inspectorate on April
15th, 2010.Results
In total, three rabbits died perioperatively, one in the
IFX-treated group and two in the placebo group, due to
anesthetic complications. Their data were excluded from
the study. The study was completed with fourteen rab-
bits treated with IFX (n = 14) and thirteen rabbits in the
placebo group (n = 13). Descriptive statistics on the rab-
bits included are shown in Table 1.
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preoperative weight was found in both groups (IFX-
treatment −8.1%; placebo: −7.7%). There was no dif-
ference in weight loss between the groups (p = 0.66). In
none of the animals an increase in body weight was
observed.
Anastomotic breaking strength
The mean value of anastomotic breaking strength in the
placebo group was 1.89 ± 0.36 N and the corresponding
value was 1.81 ± 0.33 N in the IFX-treated rabbits. There
was no statistically significant difference between the
groups (p = 0.51) (Table 1). The site of rupture was
within the anastomotic line in nineteen out of twenty-
seven (70%) rabbits, and it was similar in the two
groups. However, 30% of the anastomosis ruptured out-
side the anastomosis, which is illustrated in Figures 1
and 2. The figures shows that five of the eight anasto-
moses that ruptured outside the anastomosis had 15 or
fewer sutures, and that three of the eight anastomoses
had 16 or more sutures. The median number sutures
used in the anastomoses where 15. Furthermore, the fig-
ures also presents that five of the anastomoses that rup-
tured outside the anastomotic line was in IFX-treated
rabbits, and three in the placebo group. A supplemen-
tary analysis with these eight animals excluded was done,
and it did not have any impact on the results. It showed
only a marginal increase in anastomotic breaking
strength in the placebo-group with 0.02 N, and did not
affect the mean in the treatment group or the p-value
(data not shown). The use of different number of sutures
in the anastomoses, which also is seen in other animalPlac
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Symbols in gray are anastomoses that ruptured outside the anastomotic linstudies [26-28], was necessary to avoid anastomotic leak-
age since the intestine diameters varied in size. No dif-
ference in the use of number of sutures per anastomosis
between the groups was observed.
Histopathological analysis
Eleven rabbits in the placebo-group (84.6%) were scored
with two or more points (2 points: 23.1% and 3 points:
61.5%), and nine rabbits (64.3%) in the IFX-group
(2 points: 50.0% and 3 points: 14.3%). Only two rabbits
in the placebo group scored one point (15.4%), com-
pared to five (35.7%) in the IFX-group. No rabbits were
assessed with zero points. Thus, the placebo group had
a significant higher grade of inflammatory infiltration
response in the anastomotic site compared to the
IFX-treated rabbits (p = 0.047) (Table 2). The visual dif-
ference between slight and intense inflammatory infiltra-
tion is depicted in Figure 3A and B.
Discussion
The inflammatory reaction plays an important role in
wound healing [1,2,4,5], and since IFX has an anti-
inflammatory effect this could be one possible expla-
nation to the increased risk of anastomotic leakage that
has been reported in humans treated with IFX prior to
surgery. In the study, we found a significant lower
degree of inflammatory infiltration in the treatment
group compared to the placebo group on POD3, but
there was no significant difference in anastomotic brea-
king strength between the groups.
The ideal postoperative day for investigating anasto-
motic strength has been debated, and no consensus hasIFX
ebo
2800 3000 3200
n weight (g)
ed in Newton (N), and operation weight, measured in gram (g).
an values of anastomotic breaking strength and operation weight.
e.
IFX
Placebo
1.
4
1.
6
1.
8
2
2.
2
2.
4
A
na
st
om
ot
ic
 b
re
ak
in
g 
st
re
ng
th
 (
N
)
10 12 14 16 18
Number of sutures
Figure 2 Correlation between anastomotic breaking strength, measured in Newton (N), and numbers of sutures in the anastomosis.
● = rabbit treated with placebo, ▲ = rabbit treated with infliximab, × =mean values of anastomotic breaking strength and median value of
number of sutures. Symbols in gray are anastomoses that ruptured outside the anastomotic line.
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process at POD3 changes from the inflammatory reaction
to the proliferation phase [4], which in theory might be
the most critical time for wound dehiscence. Christensen
et al. investigated anastomotic rupture in rats at postope-
rative day 2, 4 and 6 using the bursting pressure tech-
nique. They found that 60% of the tested segments
ruptured outside the anastomosis at day 6 [29]. Although
we used a different technique than Christensen et al., our
results were in line with their findings since most of the
anastomoses in our study ruptured in the anastomotic line
at POD3 without any differences between the two groups.
To analyze the physical strength of the anastomosis,
two main methods can be used: bursting pressure and
the tension test [3]. Ikeuchi et al. concluded that tension
test, evaluated as minimal intestinal strength, is a better
method to evaluate anastomotic healing, and thatTable 2 Histological scores for each group, examined as
the overall inflammatory infiltration response in the
anastomotic site, presented as categorical data with
fraction in column percentage
Score Placebo (N = 13) Treatment (N = 14)
0 0 (0.0%) 0 (0.0%)
1 2 (15.4%) 5 (35.7%)
2 3 (23.1%) 7 (50.0%)
3 8 (61.5%) 2 (14.3%)
Total 13 (100%) 14 (100%)
Two-sided Fischer’s exact test shows that the placebo-group has a significant
higher score (p = 0.047).bursting pressure can evaluate the overall anastomotic
integrity but may reflect anastomotic healing less accu-
rately [26].
The overall inflammatory infiltration response in the
anastomotic line was graded according to a four-graded
scale. In reflection, and since TNF-α mainly is produced
by macrophages, an estimation of these cells in the anas-
tomotic site may have been interesting. Immunohisto-
chemical staining specific for TNF-α, as a complement
to hematoxylin and eosin, should preferably be used to
recognize the macrophages because they are difficult to
distinguish from fibroblasts in HE-staining.
Ågren et al. aimed to investigate whether an increase in
matrix metalloproteinase (MMP) affects the anastomotic
dehiscence in rats, and since TNF-α induces the ex-
pression of MMP activity the hypothesis was that TNF-α
indirectly might influence the pathogenesis of the anasto-
motic healing process. The authors found that the use of
TNF-α inhibitor (p38 MAP kinase inhibitor), given one
hour before anastomotic surgery and then on POD 1 and
2, prevented increased levels of TNF-α in the anastomotic
wound. However, a significant difference in anastomotic
breaking strength was not detected between the groups
[23]. This is in line with our findings, since our results
showed that the IFX group had a significant lower grade
of inflammatory response in the anastomotic site, which
could be explained by locally decreased levels of TNF-α.
In addition to this, inhibition of the TNF-α molecule's
properties, which as one of many chemical inflammatory
mediators promote leukocyte-endothelial adhesions as a
prelude to leukocyte emigration from the vessels into the
Figure 3 Histological images depicting the inflammatory infiltration response in the anastomotic site. Depicts the inflammatory
infiltration response in the anastomotic site evaluated with a four-graded scale. The inserted images show the anastomotic site at magnification
of approximately 40 x and the black arrow points at the magnified area (approximately 200 x). (A). Slight inflammatory infiltration response in a
rabbit from the control group. (B). Intense inflammatory infiltration response in a rabbit from the control group.
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grade of inflammatory response.
Iglesias et al. tested the effect of another TNF-α inhi-
bitor (etanercept) in cutaneous wound healing in mice,
and they found no significant difference in wound
healing time (measured over 20 days), morphological
changes or re-epithelialization rate between the treated
and untreated group. As in our study, they found that
the inflammatory cell counts in the wound area were
higher in the non-treated animals although this was not
statistically significant. They concluded that biological
therapies, that inhibit the effect of the TNF-α molecule,
does not affect wound healing and does not need to be
suspended preoperatively [30].
Zubaidi et al., investigated the overall expression of
cytokines in rat intestinal, facial and cutaneous wound
healing. Interestingly they found that local expression of
TNF-α on POD1, after intestinal anastomotic surgery,
significantly decreased and sustained decreased over
14 days during the postoperative period. A similar result
was found in colonic anastomosis, while increased levels
of TNF-α in cutaneous and facial wounds was observed
[24]. These finding may have clinical importance, since
it indicates that inhibition of TNF-α probably not affects
the anastomotic healing process, as a result of the al-
ready low levels of TNF-α in the wound area. However,
they did not particularly test the influence of TNF-α in-
hibition in wound healing, therefore further research is
required to elucidate this. With this in mind, it would be
very interesting to measure the serum and local anasto-
motic levels of TNF-α. In another study where the effect
of IFX on neuronal apoptosis was examined in rabbits, a
significant reduction (approx. 50%) in the blood concen-
tration of TNF-α was found two weeks after subcuta-
neous administration of a dose of 5 mg/kg [31] and in a
recent study on another TNF-α inhibitor (adalimumab),the serum concentration in rabbits was within the re-
commended level after repeated administration accor-
ding to clinical use [32]. Since we aimed to test IFX
possible influence on the intestinal healing, the treat-
ment group received the double of therapeutic dose
recommended in humans with inflammatory bowel dis-
eases. Measuring the levels of TNF-α in a venous blood
sample could have been used to validate the IFX treat-
ment in this study, but there are no reasons to believe,
that the pharmacodynamics of IFX in rabbits differ from
humans.
At last, it is also important to mention that the com-
parably small sample sizes of 13 and 14 rabbits in our
groups are only sufficient to show comparably large
effects. Small differences as seen in our study can only
be confirmed statistically by larger studies.
The present study used a single dose of IFX one week
prior to surgery. A long-term course of IFX given pre-
operatively to patients with severe symptoms of inflam-
matory bowel disease is common. In addition to this, we
used a healthy rabbit intestine, where wound healing may
differ from that seen in bowels affected with Chron’s
disease or ulcerative colitis. These facts are important
shortcomings in the comparison of the present results
with the clinical situation. We suggest that additional
studies with a long-time preoperative treatment with IFX
should be done to investigate whether IFX may have a
possible detrimental effect on the anastomotic healing
process.
Conclusion
Our conclusion, limited by the small sample sizes in
both groups, is that a single dose of IFX, given one week
prior to surgery, does not have an impact on the anasto-
motic breaking strength on the third postoperative day
in the small intestine of rabbits.
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